Tuberc Respir Dis > Volume 87(3); 2024 > Article
Kim, Shin, Yoo, Jo, and Park: Lack of Association between Inhaled Corticosteroid Use Based on the Exhaled Nitric Oxide and Acute Exacerbation of Chronic Obstructive Pulmonary Disease



Fractional exhaled nitric oxide (FeNO) is known to useful biomarker for detecting eosinophilic airway inflammation. However, there is a lack of evidence regarding the role of FeNO in chronic obstructive pulmonary disease (COPD). We aimed to assess whether elevated FeNO and its impact on treatment change into an inhaled corticosteroid (ICS)-containing regimen and association with acute exacerbation (AE) in patients with COPD.


We retrospectively analyzed 107 COPD patients without a history of asthma from March 2016 to December 2019. The patients whose FeNO value was more than 50 parts per billion (ppb) were defined into the high FeNO group. Multivariable analysis with logistic regression was used to identify factors associated with AE in COPD.


The median FeNO value was 32 ppb (interquartile range, 19 to 45) and 34 (20.0%) patients were classified as high FeNO group (median 74 ppb). In the high FeNO group, changes in inhaler treatment into an ICS-containing regimen occurred in 23 of 34 patients after the measurement of FeNO. In multivariate analysis, high FeNO was not a contributing factor for AE, but only the high blood eosinophil count (≥300 cells/μL) was associated with AE (adjusted odds ratio, 2.63; 95% confidence interval, 1.01 to 6.91; p=0.049).


High FeNO value had a significant impact on the prescription of ICSs in COPD patients, but it did not show a significant association with AE either on its own or with changes in treatment.


Chronic obstructive pulmonary disease (COPD) is characterized by a combination of small airway disease and parenchymal destruction due to airway inflammation and remodeling [1]. Airway inflammation in COPD is generally thought to be primarily characterized by neutrophils and CD8+ lymphocytes. However, some COPD patients exhibit a component of Th2-mediated airway inflammation [2] with increased numbers of eosinophils in lung tissue and sputum compared to healthy controls [3,4]. When these COPD patients experience frequent exacerbations, inhaled corticosteroids (ICS) are recommended in addition to long-acting bronchodilators [5]. Notably, higher blood eosinophil counts predict a greater response to ICS in several COPD randomized controlled trials [6-10].
Fractional exhaled nitric oxide (FeNO) serves as another useful biomarker for detecting eosinophilic airway inflammation because it is modestly associated with both sputum and blood eosinophils [11], and its measurement is simple and non-invasive. While FeNO measurement has not yet been officially endorsed as a diagnostic tool for asthma, it is widely utilized as a significant biomarker for eosinophilic inflammation in asthma due to its usefulness and value as a predictor of ICS initiation and response evaluation in numerous research [12-14].
Regarding COPD, several studies have reported that FeNO might predict the ICS response in COPD as well, but the role of FeNO in COPD remains controversial [15]. In addition, the utility of FeNO has been highlighted in asthma and partly in COPD with exacerbation. Therefore, our study aimed to assess whether elevated FeNO and its impact on treatment change into an ICS-containing regimen, and its association with acute exacerbation (AE) in COPD patients without a history of asthma in real-world clinics.

Materials and Methods

1. Study population

This study included only patients diagnosed with COPD who were measured for FeNO from March 2016 to December 2019 at two referral hospitals: Samsung Medical Center and Kangdong Sacred Heart Hospital. The definition of COPD was based on compatible medical history and fixed airflow limitation on spirometry (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity ratio <70%) [5]. Patients previously diagnosed with asthma by a physician and those with lung cancer who underwent lung resection surgery were excluded. Patients without a recorded blood eosinophil value at the time of FeNO measurement were also excluded. All patients were followed up for at least 6 months after the FeNO measurement.
This study obtained approval from the Samsung Medical Center Institutional Review Board (IRB no. 2020-11-158). Informed consent was waived because patient information was de-identified and anonymized before the analysis.

2. Data collection

Baseline demographic data, smoking status, comorbidities, modified Medical Research Council (mMRC) dyspnea dyspnea scale, subjective wheezing, and patient-reported disease-related quality of life (QoL) status assessed by COPD assessment test score were collected by physicians using electronic case-report forms. Blood eosinophil count and FeNO were measured and baseline pulmonary function test results and the previous AE history within the last year were also recorded.
Prescribed inhaler regimens were reviewed before and after FeNO measurement. Moderate AE was defined as an acute worsening of respiratory symptoms that resulted in additional treatment with systemic steroids and/or antibiotics, while severe AE was defined as an AE leading to hospitalization [16].

3. Spirometry and FeNO measurement

Spirometry was performed using standardized equipment following the guidelines established by the American Thoracic Society (ATS) and the European Respiratory Society [17]. Predicted percentage values for the spirometry results were calculated using equation developed for Korean populations [18].
FeNO levels were measured according to ATS guideline recommendation [19]. Patients were instructed to inhale a maximum amount of air outside the valve, then exhale into the valve, which was connected to a chemiluminescent NO analyzer (NIOX MINO, Aerocrine AB, Solna, Sweden). Patients with FeNO values greater than 50 parts per billion (ppb) were classified as the high FeNO group in this study [20,21].

4. Statistical analysis

Data are presented as numbers (%) for categorical variables and median (interquartile range [IQR]) for continuous variables. Continuous data between groups were compared using the Mann-Whitney test, and categorical data were compared using a chi-square test or Fisher’s exact test. Multivariable analysis with logistic regression was conducted to identify independent factors associated with AE in COPD, fully adjusted for age, sex, smoking history, mMRC, FEV1, history of AE, high FeNO, high blood eosinophil, and initiation of ICS-containing inhalers after FeNO measurement. Statistical differences were considered significant at p<0.05. All statistical analyses were performed using SPSS version 27 (IBM Co., Armonk, NY, USA).


1. Baseline characteristics

A total of 170 COPD patients were included in this study, with a median age of 69 (IQR, 62 to 75), and males accounting for 88.8%. Most of the patients (86.3%) were ex- or current smokers and had a mean smoking history of 40 pack-years. The mean FeNO value for all patients was 32 ppb (IQR, 19 to 45), and they were classified into the high FeNO group (n=34, 20%) and low FeNO group (n=136, 80%).
A comparison of baseline clinical features between the two FeNO groups is shown in Table 1. There were no significant differences in age, sex, body mass index, and proportion of ex- or current smokers and smoking pack-years between the two groups. Comorbidities such as allergic rhinitis, atopy, and drug allergy history were more prevalent in the high FeNO group than in the low FeNO group (32.4% vs. 11.0%, p=0.002). The severity of dyspnea and disease-related QoL status were similar, but post-bronchodilator FEV1 was significantly higher in the high FeNO group. Previous exacerbation history did not differ between the groups, and the proportion of patients with blood eosinophil counts over 300 cells/µL also did not differ significantly (p=0.469).

2. Changes in treatment after FeNO measurement

The use of inhalers before and after FeNO measurement is presented in Table 2. In the high FeNO group, a higher proportion of patients did not use inhalers as maintenance treatment before the FeNO measurement (32.4% vs. 15.4%, p=0.024). Among those who received inhaler treatment before the FeNO measurement, there was no significant difference in the type of inhaler use between the two groups based on FeNO value. However, after FeNO measurement, long-acting muscarinic antagonist (LAMA)/long-acting beta-agonist (LABA) combined inhalers were more commonly prescribed to the low FeNO group (11.8% vs. 47.1%), and ICS-containing inhalers were used more frequently in the high FeNO group (88.2% vs. 44.8%).
In the high FeNO group, 11 (32.4%) patients were not on maintenance inhalers and started them after FeNO measurement. All 11 patients initiated treatment with an ICS-containing inhaler (four with triple therapy with ICS, LABA, LAMA; and seven with ICS & LABA or ICS & LAMA). In the low FeNO group, 21 (15.4%) patients were not on maintenance inhalers. After FeNO measurement, 17 patients started treatment and the other four remained untreated. Among the 17 who started treatment, one was on LAMA, nine on LAMA & LABA, three on ICS & LABA or ICS & LAMA, and four on triple therapy. In the low FeNO group, less than half of those who initiated treatment (7/17, 41%) used an ICS-containing inhaler.
In the high FeNO group, a significant number of changes in inhaler prescriptions occurred. Before the measurement of FeNO, only nine (26.5%) patients used ICS-containing inhalers, but after the measurement, 30 (88.2%) patients used ICS-containing inhalers (Figure 1).

3. Risk factors related to follow-up AE of COPD

During the 6 months of the follow-up period, AE events occurred in 48 (28.2%) patients, and severe AE occurred in nine (5.3%) patients. Total moderate AE events and severe AEs developed in eight (23.5%) and one (2.9%) in the high FeNO group, and 40 (29.4%) and eight (5.9%) in the low FeNO group, respectively, without statistical significance. There were no significant differences in total AE events between ICS-containing inhalers and non-ICS-containing inhalers in both the low FeNO group and the high FeNO group (Figure 2).
The analysis of risk factors related to total AE is described in Table 3. In multivariable analysis, a high blood eosinophil count (≥300 cells/µL) was associated with an increased risk of total AE (adjusted odds ratio, 2.63; 95% confidence interval, 1.01 to 6.91; p=0.049). However, a high FeNO value was not found to be a significant risk factor for total AE in multivariable analysis. The initiation of ICS-containing inhalers after FeNO measurement did not demonstrate a significant effect on the occurrence of total AE.


In our study, more than half of the COPD patients experienced a change in the inhaler prescription after FeNO measurement, particularly notable in the high FeNO group, where more ICS-containing inhalers were prescribed. However, we did not find a significant association between ICS use and the risk of exacerbation at 6 months based on the FeNO group. In addition, we found no significant impact of high FeNO on the risk of exacerbation, while high blood eosinophil count (≥300 cells/µL) was associated to an increased risk of exacerbation.
Although the basis of COPD treatment is inhaled long-acting bronchodilators, a considerable number of patients require ICS treatment concurrently. COPD is a heterogeneous disease, and as many as 30% to 40% of patients exhibit clinical signs of eosinophilic inflammation in either their blood or sputum [22]. Furthermore, the use of ICS-containing inhalers has shown a favorable response in terms of reducing exacerbations when patients have clinical features related to a high Th2-cell signature, including a previous history of asthma and objective parameters indicating eosinophilic airway inflammation [23,24]. Indeed, a blood eosinophil count ≥300 cells/μL has been reported as a significant predictor of a reduced risk of future exacerbation in response to ICS treatment in COPD [25] In this context, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations suggest adding ICS treatment to bronchodilators as initial treatment for patients with a high blood eosinophil (≥300 cells/μL) and an elevated risk of exacerbation [5,26]. However, although eosinophils in sputum or blood are regarded as promising biomarkers for eosinophilic airway inflammation and for predicting the effect of ICS, some limitations exist, including limited accessibility to technicians and potential variations in tests for sputum eosinophil measurement, and concerns about other disease leading to high blood eosinophils and reproducibility of measurements between tests of blood eosinophils [23,27,28]. FeNO is considered an alternative parameter for eosinophilic airway inflammation, but its clinical effectiveness has been highlighted primarily in asthma and partly in COPD, especially in exacerbation status [29,30]. The clinical evidence for the role of FeNO in stable COPD is lacking because FeNO measurement is not mandatory in COPD assessment. Thus, there are no criteria for measuring FeNO in COPD patients, nor guidelines for prescribing ICS based on FeNO values. In a study of 160 stable COPD patients, FeNO was found to be highly correlated with findings of Th2 inflammation, including a history of asthma and subjective wheezing. However, the role of FeNO was only subsidiary in the use of ICS-containing inhaler treatment [31]. Due to the limited role of FeNO in COPD patients, clinicians may consider using ICS in COPD patients based on other clinical features rather than FeNO values.
In the present study, we assessed the association between FeNO values and ICS use and further examined the association with six-month exacerbation risk. FeNO values were measured using the same NO analyzers, NIOX MINO, in two hospitals, ensuring the reliability of the measured values according to the test methods. We demonstrated that more ICS was prescribed in the high FeNO group (≥50 ppb), but there were no significant results regarding exacerbation risk after ICS use in both the high FeNO group and low FeNO group. The possible explanations for the non-significant association between ICS use and exacerbation even in the high FeNO group might be a weak biomarker of FeNO representing eosinophilic inflammation in COPD patients because FeNO can be affected by age, gender, smoking, and dietary factors [32]. Another explanation can be the different mechanisms of FeNO elevation in COPD patients. The level of exhaled NO is usually increased and mediated by the inducible nitric oxide synthase enzyme, whose activity is elevated during certain inflammatory processes. Pedoto et al. [33] suggested that acidosis caused systemic hypotension and activated myeloperoxidase activity, which was associated with increased FeNO levels.
A single measurement could affect our results. In one prospective study, patients with COPD who consistently had FeNO values consistently higher than 20 ppb on at least two occasions showed a higher risk of AE [34]. However, in contrast to this study, our findings indicate that when the FeNO value measured once exceeded 20 ppb, there was no significant difference in AE compared to patients who never had a FeNO value exceeding 20 ppb. In our study, baseline FeNO was measured only once to assess its relationship with AE, similar to the results shown in the aforementioned study, and we found no significant association with AE development. Repeating FeNO measurements was not feasible due to the lack of coverage by health insurance and the test is not recommended as an essential diagnostic modality in COPD. Consequently, we were unable to identify patients with consistently elevated FeNO values. Thus, the association between a high FeNO value measured once and the risk of exacerbation may be limited in interpretation. Rouhos et al. [35] suggested that the short-term repeatability of FeNO measurements in COPD patients was comparable to that in healthy subjects. Further analysis of the effect of changes in the FeNO value beyond the minimum measurement changes and persistently elevated FeNO values in serial measurements on exacerbations will be needed.
Our study has several limitations. Firstly, due to its retrospective nature, we included patients with COPD irrespective of their smoking status and current use of ICS. These factors could potentially influence the level of FeNO [36]. Second, the measurement of FeNO in COPD is not deemed essential for diagnosis, assessing severity, or predicting future AE risk. We only included patients with FeNO values recorded during their initial assessment at referral hospitals, which might introduce selection bias. Third, since the FeNO values were measured only once in this study, we were unable to identify individuals with persistently high FeNO levels. Lastly, the small number of patients in each FeNO group may have resulted in insufficient statistical power to obtain clinically significant results.
In conclusion, our findings indicate that a high FeNO value influenced clinicians to prescribe more ICS in real-world clinics. However, we did not identify FeNO as a predictor or risk reduction strategy of exacerbation. Further studies are warranted to evaluate the effect of ICS use in patients with COPD based on FeNO measurement on prognosis, including the risk of AE.


Authors’ Contributions

Conceptualization: Jo YS, Park HY. Methodology: Kim BG, Jo YS, Park HY. Formal analysis: Kim BG, Park HY. Data curation: Kim BG, Shin SH, Jo YS, Park HY. Software: Kim BG, Jo YS, Park HY. Validation: all authors. Investigation: Kim BG, Shin SH, Jo YS, Park HY. Writing - original draft preparation: Kim BG. Writing - review and editing: Shin SH, Jo YS, Park HY. Approval of final manuscript: all authors.

Conflicts of Interest

Yong Suk Jo is an editor of the journal, but she was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.


No funding to declare.

Fig. 1.
Changes in inhaler use before and after fractional exhaled nitric oxide (FeNO) measurement. (A) Low FeNO group. (B) High FeNO group. Data are presented as number (%). ICS: inhaled corticosteroid.
Fig. 2.
Total acute exacerbation events between inhaled corticosteroid (ICS)-containing inhaler and non-ICS-containing inhaler in both low fractional exhaled nitric oxide (FeNO) group and high FeNO group. Data are presented as percentage.
Table 1.
Baseline characteristics (n=170)
Variable Total (n=170) High FeNO (n=34) Low FeNO (n=136) p-value
Age, yr 69 (62-75) 70 (65-75) 69 (62-75) 0.419
Male sex 151 (88.8) 31 (91.2) 120 (88.2) 0.768
Body mass index, kg/m2 23.5 (21.5-25.7) 23.3 (21.8-25.2) 23.7 (21.1-26.0) 0.649
Smoking history (n=167) 0.337
 Never-smoker 23 (13.8) 3 (8.8) 20 (15.0)
 Ex-smoker 108 (64.7) 26 (76.5) 82 (61.7)
 Current smoker 36 (21.6) 5 (14.7) 31 (23.3)
 Pack-year (n=142)* 40 (27-50) 40 (22-50) 40 (30-50) 0.558
 Previous history of TB/NTM 25 (14.7) 7 (20.6) 18 (13.2) 0.279
 AR/Atopy/Drug allergy 26 (15.3) 11 (32.4) 15 (11.0) 0.002
 Hypertension 64 (37.6) 13 (38.2) 51 (37.5) 0.937
 Diabetes mellitus 34 (20.0) 8 (23.5) 26 (19.1) 0.565
 Cardiovascular disease 23 (13.5) 4 (11.8) 19 (14.0) 1.000
 Congestive heart failure 15 (8.8) 1 (2.9) 14 (10.3) 0.309
 Cerebrovascular disease 10 (5.9) 2 (5.9) 8 (5.9) 1.000
 Lung cancer 5 (2.9) 0 5 (3.7) 0.584
 Other malignancy 33 (19.4) 7 (20.6) 26 (19.1) 0.846
mMRC (n=141)
 ≥Grade 2 34 (24.1) 5 (16.1) 29 (26.4) 0.239
Baseline CAT score (n=148) 16 (9-22) 13 (10-18) 17 (9-23) 0.199
Subjective wheezing 25 (14.7) 8 (23.5) 17 (12.5) 0.104
Baseline lung function
 Post-BD FVC, L 3.30 (2.84-3.95) 3.64 (2.98-4.12) 3.24 (2.78-3.80) 0.052
 Post-BD FVC, % 81 (71-90) 85 (76-95) 79 (70-89) 0.074
 Post-BD FEV1, L 1.86 (1.46-2.27) 2.08 (1.60-2.41) 1.80 (1.42-2.17) 0.030
 Post-BD FEV1, % 65 (56-74) 69 (56-81) 64 (53-73) 0.033
 FEV1 <50% 31 (18.2) 4 (11.8) 27 (19.9) 0.275
 Post-BD FEV1/FVC 57 (49-62) 59 (54-62) 56 (48-63) 0.333
 BDR positivity 32 (18.8) 5 (14.7) 27 (19.9) 0.492
 DLco, % (n=68) 86 (72-96) 88 (78-96) 85 (68-97) 0.538
History of AE in previous 1 year 0.645
 Yes 84 (49.4) 18 (52.9) 66 (48.5)
 Severe AE 16 (9.4) 2 (5.9) 14 (10.3) 0.742
Blood eosinophil count, cells/µL
 ≥300 cells/µL 28 (16.5) 7 (20.6) 21 (15.4) 0.469
FeNO, ppb 32 (19-45) 74 (58-101) 25 (17-37) <0.001

Values are presented as median (interquartile range) or number (%).

* Pack-year information of two ever smoker is unknown.

Prostate cancer (n=8), esophagus cancer (n=5), gastric cancer (n=5), bladder cancer (n=3), larynx cancer (n=3), rectal cancer (n=3), breast cancer (n=1), lymphoma (n=1), thymic carcinoma (n=1), thyroid cancer (n=1), renal cell carcinoma (n=1).

≥1 hospitalization.

FeNO: fractional exhaled nitric oxide; TB: tuberculosis; NTM: nontuberculous mycobacteria; AR: allergic rhinitis; mMRC: modified Medical Research Council; CAT: COPD assessment test; BD: bronchodilator; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; BDR: bronchodilator response; DLco: diffusing capacity for carbon monoxide; AE: acute exacerbation; ppb: parts per billion.

Table 2.
Changes in treatment after FeNO measurement (n=170)
Variable Total (n=170) High FeNO (n=34) Low FeNO (n=136) p-value
Treatment before FeNO measurement
 No treatment 32 (18.8) 11 (32.4) 21 (15.4) 0.024
 LAMA or LABA 20 (11.8) 3 (8.8) 17 (12.5) 0.768
 LAMA/LABA combined 74 (43.5) 11 (32.4) 63 (46.3) 0.142
 ICS & LABA or ICS & LAMA 16 (9.4) 2 (5.9) 14 (10.3)
 Triple (ICS & LABA & LAMA) 28 (16.5) 7 (20.6) 21 (15.4)
 Any ICS use 44 (25.9) 9 (26.5) 35 (25.7) 0.930
Treatment after FeNO measurement
 No treatment 4 (2.4) 0 4 (2.9) 0.585
 LAMA or LABA 7 (4.1) 0 7 (5.1) 0.347
 LAMA/LABA combined 68 (40.0) 4 (11.8) 64 (47.1) <0.001
 ICS & LABA or ICS & LAMA 35 (20.6) 17 (50.0) 18 (13.2)
 Triple (ICS & LABA & LAMA) 56 (32.9) 13 (38.2) 43 (31.6)
 Any ICS use 91 (53.5) 30 (88.2) 61 (44.8) <0.001
Changes in treatment after FeNO measurement 76 (44.7) 21 (61.8) 55 (40.4) 0.025
Newly started ICS 62 (36.5) 21 (61.8) 41 (30.1) <0.001

Values are presented as number (%).

FeNO: fractional exhaled nitric oxide; LAMA: long-acting muscarinic antagonist; LABA: long-acting beta-agonist; ICS: inhaled corticosteroid.

Table 3.
Risk factors associated with follow-up AE (n=170)
Variable Univariable
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI)* p-value
Age, yr 1.01 (0.98-1.05) 0.444 1.02 (0.98-1.07) 0.323
Male sex 2.26 (0.63-8.16) 0.211 3.00 (0.50-18.01) 0.230
Body mass index, kg/m2 1.02 (0.97-1.07) 0.477 1.02 (0.97-1.08) 0.453
Smoking history, yes 1.48 (0.52-4.25) 0.464 0.93 (0.25-3.41) 0.910
mMRC ≥grade 2 0.71 (0.30-1.68) 0.436 0.59 (0.23-1.52) 0.271
Baseline FEV1, %
 FEV1 <50% Reference Reference
 FEV1 ≥50% 0.95 (0.40-2.25) 0.913 0.68 (0.21-2.19) 0.520
History of AE in previous 1 year, yes 2.10 (1.06-4.16) 0.034 1.34 (0.62-2.91) 0.454
High FeNO (≥50 ppb) 0.74 (0.31-1.77) 0.497 0.51 (0.19-1.36) 0.175
High blood eosinophil (≥300 cells/µL) 1.84 (0.79-4.28) 0.159 2.63 (1.01-6.91) 0.049
Newly started ICS-containing inhalers 1.24 (0.63-2.44) 0.532 1.82 (0.81-4.07) 0.146

* Adjusted for age, sex, smoking history, mMRC, FEV1, history of AE, high FeNO, high blood eosinophil, and newly started ICS-containing inhalers.

AE: acute exacerbation; OR: odds ratio; CI: confidential interval; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 second; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroid.


1. Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int 2014;2014:271918.
crossref pmid pmc pdf
2. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13.
crossref pmid
3. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000;15:109-15.
crossref pmid
4. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
crossref pmid pmc
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report) [Internet]. Fontana: GOLD; 2023 [cited 2024 Mar 14]. Available from:

6. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-5.
crossref pmid pmc
7. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018;6:117-26.
crossref pmid
8. Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, et al. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020;202:660-71.
crossref pmid pmc
9. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378:1671-80.
crossref pmid
10. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076-84.
crossref pmid
11. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-27.
crossref pmid pmc
12. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013;132:821-7.
crossref pmid
13. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med 1995;152:892-6.
crossref pmid
14. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8.
crossref pmid
15. Lu Z, Huang W, Wang L, Xu N, Ding Q, Cao C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2018;13:2695-705.
crossref pmid pmc pdf
16. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J 2018;52:1801261.
crossref pmid
17. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
crossref pmid
18. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis 2005;58:230-42.
19. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.
crossref pmid pmc
20. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005;172:453-9.
crossref pmid
21. Dummer JF, Epton MJ, Cowan JO, Cook JM, Condliffe R, Landhuis CE, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009;180:846-52.
crossref pmid
22. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-700.
crossref pmid
23. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016;71:118-25.
crossref pmid pmc
24. Su VY, Yang KY, Yang YH, Tsai YH, Perng DW, Su WJ, et al. Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma. J Allergy Clin Immunol Pract 2018;6:1927-35.
crossref pmid
25. Jo YS, Hwang YI, Yoo KH, Kim TH, Lee MG, Lee SH, et al. Effect of inhaled corticosteroids on exacerbation of asthma-COPD overlap according to different diagnostic criteria. J Allergy Clin Immunol Pract 2020;8:1625-33.
crossref pmid
26. Global Initiative for Chronic Obstructive Lung Disease. 2020 Global strategy for prevention, diagnosis and management of COPD [Internet]. Fontana: GOLD; 2020 [cited 2024 Mar 14]. Available from:

27. Oshagbemi OA, Burden AM, Braeken DC, Henskens Y, Wouters EF, Driessen JH, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med 2017;195:1402-4.
crossref pmid
28. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am J Respir Crit Care Med 2016;193:965-74.
crossref pmid
29. Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010;15:472-7.
crossref pmid
30. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation 2013;36:1178-85.
crossref pmid pdf
31. Jo YS, Choe J, Shin SH, Koo HK, Lee WY, Kim YI, et al. Exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease: clinical implications of the use of inhaled corticosteroids. Tuberc Respir Dis (Seoul) 2020;83:42-50.
crossref pmid pmc pdf
32. Abba AA. Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann Thorac Med 2009;4:173-81.
crossref pmid pmc
33. Pedoto A, Caruso JE, Nandi J, Oler A, Hoffmann SP, Tassiopoulos AK, et al. Acidosis stimulates nitric oxide production and lung damage in rats. Am J Respir Crit Care Med 1999;159:397-402.
crossref pmid
34. Alcazar-Navarrete B, Ruiz Rodriguez O, Conde Baena P, Romero Palacios PJ, Agusti A. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J 2018;51:1701457.
crossref pmid
35. Rouhos A, Kainu A, Piirila P, Sarna S, Lindqvist A, Karjalainen J, et al. Repeatability of exhaled nitric oxide measurements in patients with COPD. Clin Physiol Funct Imaging 2011;31:26-31.
crossref pmid pmc pdf
36. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-722.
crossref pmid

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next